LDS/Medical Tests/Hepatitis Be Antibody

Hepatitis Be Antibody

Hepatitis B infection is caused by the Hepatitis B Virus. Hepatitis B virus is spread by contact with contaminated blood and body fluids. Chronic infection with Hepatitis B virus results in damage to the liver, ultimately resulting in liver disease including cirrhosis and/or liver cancer. The body’s immune system is responsible for the liver tissue damage because it destroys the liver cells containing the virus. Consumption of alcohol during infection with Hepatitis B virus is discouraged as it can increase the damage to the liver. Infection with Hepatitis B virus is prevented by cautious and safe handling of blood or body fluids and also by vaccination.

Serology testing to detect hepatitis B surface antigen is the standard for diagnosing the disease. Hepatitis B surface antigen is produced by the virus itself and is used to detect a current infection of Hepatitis B. Antibody to Hepatitis B surface antigen is tested for immunity acquired from the hepatitis B vaccine. Hepatitis Be Antigen and hepatitis Be antibody are tested in cases of chronic hepatitis B infections. Hepatitis Be antigen is present when infection is active. Absence of HBe antigen and the presence of Anti-HBe indicate successful treatment.

Hepatitis B core antibody is the most commonly detected antibody in the disease. Total Anti-HBc antibody testing includes IgG and and IgM to HBc antigen. Total Anti-HBc will be positive indefinitely, whereas IgM is usually positive for 3 to 6 months after acute viral infection. HBc assays should not be used to test for acute Hepatitis B virus infection.

Anti-HBc IgM titers increase rapidly, peak during the acute infection stage of HBV infection, and then fall to a relatively low level as the patient recovers or becomes a chronic carrier. Anti-HBc IgM titers are useful in the diagnosis of acute HBV infection when HBsAg concentrations are below the sensitivity of the diagnostic assay and anti-HBs have not yet appeared (the “core window” period). Anti-HBc IgM may be the only specific marker for the diagnosis of acute HBV infection. The use of viral markers such as HBsAg, anti-HBs, and anti-HBc total to differentiate acute from chronic hepatitis B is inconclusive because most of these markers are also seen in chronic infection.

  • Diagnosis of acute/current hepatitis B infection
  • In combination with other hepatitis B virus (HBV) marker assays is used to define the clinical status of known HBV infected patients
  • In combined with other HBV, HAV (hepatitis A virus), and HCV (hepatitis C virus) assays for the diagnosis of patients presenting symptoms of acute viral hepatitis
  • Aid in the differentiation of a hepatitis of unknown origin

Positive in:

  • Current hepatitis B infection
  • Hepatitis B carriers
  • Exposure to hepatitis B infection

Negative (Non-reactive)

Enzyme immunoassay, Chemiluminescent immunoassay.

Serum (SST), plasma (EDTA). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
HBV DNA by PCR (quantitative), HBsAg, HBeAg, Anti-HBe, HAV antibody, HCV antibody, Liver panel, Acute Hepatitis Profile, Lactate Dehydrogenase, Liver biopsy.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Clin Liver Dis. 2004;8:267. [PMID: 15481340]
  • Gastroenterol Clin Biol. 2008 Jan;32(1 Pt 2):S56-63. [PMID: 18662611]
  • N Engl J Med. 2004 Mar 11;350(11):1118-29. [PMID: 15014185]
  • Stevens, CD. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company (2010).
  • Burtis C, Ashwood E, and Bruns D. Fundamentals of Clinical Chemistry. St. Louis: Saunders (2008).